FDAnews
www.fdanews.com/articles/182987-fda-approves-jazzs-vyxeos-for-aml-variants
ApprovedGreen.gif

FDA Approves Jazz’s Vyxeos for AML Variants

August 8, 2017

The FDA approved Vyxeos, the brand name for Jazz Pharamaceuticals’ combination of the chemotherapy drugs daunorubicin and cytarabine, for the treatment of adults with two types of poor-prognosis acute myeloid leukemia: newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Vyxeos may help some patients live longer than if they were to receive the two therapies separately, the agency said.

T-AML occurs as a complication of chemotherapy or radiation in approximately 8 to10 percent of all patients receiving those treatments for cancer. AML-MRC is characterized by a history of certain blood disorders and mutations within cancer cells.

View today's stories